+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07102628

Randomized Study of Early Inclisiran Treatment in Hospitalized Patients With Acute Coronary Syndromes Compared to Placebo With Standard Care

Led by Novartis Pharmaceuticals · Updated on 2026-09-16

300

Participants Needed

69

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of inclisiran in people with serious heart conditions known as acute coronary syndromes ACS, including STEMI or NSTEMI, when this treatment is started early after hospital admission. The study compares inclisiran to a placebo, both given alongside standard treatment, to understand its impact. This is a randomized, double-blind, placebo-controlled clinical trial involving two groups. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection at randomization Day 1 and again on Day 90. The treatment is given on top of standard treatments, including high-intensity statins or non-statin therapies for those intolerant to statins. The study includes a screening visit within 7 days of hospital admission, randomization before or at discharge, a 150-day double-blind treatment period, scheduled safety calls between visits, and a safety follow-up call 30 days after the end of the study. During the study, participants will have assessments of LDL cholesterol and other blood lipids at multiple time points, including baseline, Day 30, Day 90, and Day 150. Safety and efficacy will be closely monitored through visits and telephone calls. The primary outcome measured is the percent change in LDL cholesterol from baseline to Day 150. The total participation duration is approximately 150 days with careful follow-up to evaluate the treatment effects and safety.

CONDITIONS

Brief Title

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here